97 related articles for article (PubMed ID: 7475290)
1. Evaluation of in vivo induction of apoptosis in patients with acute leukemia treated on a phase I study of paclitaxel.
Seiter K; Feldman EJ; Traganos F; Li X; Halicka HD; Darzynkiewicz Z; Lederman CA; Romero MB; Ahmed T
Leukemia; 1995 Nov; 9(11):1961-6. PubMed ID: 7475290
[No Abstract] [Full Text] [Related]
2. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
Kantarjian HM; Beran M; O'Brien S; Robertson L; Siddik Z; Yoshida M; Yang LY; Rios MB; Keating MJ; Meyer M
Leukemia; 1996 Mar; 10(3):396-401. PubMed ID: 8642853
[TBL] [Abstract][Full Text] [Related]
4. [Chemotherapy of leukemia].
Oono R
Nihon Naika Gakkai Zasshi; 1997 Mar; 86(3):477-80. PubMed ID: 9198635
[No Abstract] [Full Text] [Related]
5. P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia.
Carulli G; Petrini M; Marini A; Vaglini F; Caracciolo F; Grassi B
Haematologica; 1990; 75(6):516-21. PubMed ID: 1982999
[TBL] [Abstract][Full Text] [Related]
6. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.
Feldman E; Arlin Z; Ahmed T; Mittelman A; Puccio C; Chun H; Cook P; Baskind P
Leukemia; 1992 Nov; 6(11):1185-8. PubMed ID: 1434802
[TBL] [Abstract][Full Text] [Related]
7. [Experience with using aclarubicin in the treatment of acute leukemia and blast crisis of chronic myeloid leukemia].
Savchenko VG; Isaev VG; Abakumov EM; Khoroshko ND; Turkina AG; Sokolov AN; Viadro MM; Navashin SM
Antibiot Khimioter; 1992 Jul; 37(7):47-9. PubMed ID: 1456812
[TBL] [Abstract][Full Text] [Related]
8. Continuous infusion diaziquone and etoposide: a phase I study in adult patients with acute leukemia.
Lee EJ; Reck K; Schiffer CA
Leukemia; 1990 Mar; 4(3):189-92. PubMed ID: 2314118
[TBL] [Abstract][Full Text] [Related]
9. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
10. Outcome after cessation of therapy in childhood leukemia. A population-based Nordic study of 986 patients.
Nygaard R; Moe PJ
Acta Paediatr Scand Suppl; 1989; 354():1-24. PubMed ID: 2596294
[No Abstract] [Full Text] [Related]
11. Phase I study of continuous infusion 6-thioguanine in patients with acute leukemia.
Powell BL; Lyerly ES; Motsinger CP; Cruz JM; Chorley HM; Hurd DD; Cooper MR
Leukemia; 1995 May; 9(5):770-3. PubMed ID: 7769838
[TBL] [Abstract][Full Text] [Related]
12. Leukemia.
McKenna SJ
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2000 Feb; 89(2):137-9. PubMed ID: 10673646
[No Abstract] [Full Text] [Related]
13. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the understanding and treatment of pediatric leukemias.
Maloney KW; Giller R; Hunger SP
Adv Pediatr; 2012; 59(1):329-58. PubMed ID: 22789585
[No Abstract] [Full Text] [Related]
15. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.
Rea D; Legros L; Raffoux E; Thomas X; Turlure P; Maury S; Dupriez B; Pigneux A; Choufi B; Reman O; Stéphane D; Royer B; Vigier M; Ojeda-Uribe M; Recher C; Dombret H; Huguet F; Rousselot P; ;
Leukemia; 2006 Mar; 20(3):400-3. PubMed ID: 16437142
[TBL] [Abstract][Full Text] [Related]
16. Selective killing of malignant cells from leukemic patients by alkyl-lysophospholipid.
Verdonck LF; Witteveen EO; van Heugten HG; Rozemuller E; Rijksen G
Cancer Res; 1990 Jul; 50(13):4020-5. PubMed ID: 2354451
[TBL] [Abstract][Full Text] [Related]
17. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot G; Weber G
Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
[TBL] [Abstract][Full Text] [Related]
18. Leukemias and plasma cell myeloma.
Wiernik PH
Cancer Chemother Biol Response Modif; 1997; 17():390-407. PubMed ID: 9551222
[No Abstract] [Full Text] [Related]
19. Leukemias and plasma cell myeloma.
Wiernik PH
Cancer Chemother Biol Response Modif; 1999; 18():268-92. PubMed ID: 10800488
[No Abstract] [Full Text] [Related]
20. Consistent genetic abnormalities in human cancers as targets for selective therapies.
Clarkson BD
Mt Sinai J Med; 1992 Oct; 59(5):400-4. PubMed ID: 1435835
[No Abstract] [Full Text] [Related]
[Next] [New Search]
